Trial Outcomes & Findings for Efficacy and Safety Study of SUNPG1623 (NCT NCT02980692)
NCT ID: NCT02980692
Last Updated: 2023-01-27
Results Overview
The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
COMPLETED
PHASE2
391 participants
week 24
2023-01-27
Participant Flow
Participant milestones
| Measure |
SUNPG1623 I
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Placebo
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
|---|---|---|---|---|---|
|
Double Blind Placebo Controlled Period
STARTED
|
78
|
79
|
77
|
78
|
79
|
|
Double Blind Placebo Controlled Period
COMPLETED
|
62
|
64
|
60
|
71
|
74
|
|
Double Blind Placebo Controlled Period
NOT COMPLETED
|
16
|
15
|
17
|
7
|
5
|
|
Double-blind Follow-up Period
STARTED
|
62
|
64
|
60
|
71
|
74
|
|
Double-blind Follow-up Period
COMPLETED
|
62
|
61
|
56
|
67
|
69
|
|
Double-blind Follow-up Period
NOT COMPLETED
|
0
|
3
|
4
|
4
|
5
|
Reasons for withdrawal
| Measure |
SUNPG1623 I
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Placebo
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
|---|---|---|---|---|---|
|
Double Blind Placebo Controlled Period
Adverse Event
|
1
|
2
|
1
|
2
|
0
|
|
Double Blind Placebo Controlled Period
Lost to Follow-up
|
1
|
0
|
1
|
1
|
0
|
|
Double Blind Placebo Controlled Period
Investigator Decision
|
0
|
0
|
0
|
2
|
0
|
|
Double Blind Placebo Controlled Period
Withdrawal by Subject
|
2
|
1
|
1
|
2
|
4
|
|
Double Blind Placebo Controlled Period
Protocol Violation
|
2
|
0
|
1
|
0
|
0
|
|
Double Blind Placebo Controlled Period
Other
|
1
|
0
|
0
|
0
|
1
|
|
Double Blind Placebo Controlled Period
Failure to show sufficient response to treatment at Week 24
|
9
|
12
|
13
|
0
|
0
|
|
Double-blind Follow-up Period
Adverse Event
|
0
|
0
|
0
|
1
|
1
|
|
Double-blind Follow-up Period
Failure to show sufficient response to treatment at Week 24
|
0
|
2
|
1
|
0
|
0
|
|
Double-blind Follow-up Period
Lost to Follow-up
|
0
|
0
|
1
|
0
|
0
|
|
Double-blind Follow-up Period
Pregnancy
|
0
|
0
|
1
|
1
|
0
|
|
Double-blind Follow-up Period
Withdrawal by Subject
|
0
|
1
|
0
|
1
|
1
|
|
Double-blind Follow-up Period
Other
|
0
|
0
|
1
|
1
|
3
|
Baseline Characteristics
Efficacy and Safety Study of SUNPG1623
Baseline characteristics by cohort
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Total
n=391 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Continuous
|
50.1 years
STANDARD_DEVIATION 13.28 • n=39 Participants
|
49.3 years
STANDARD_DEVIATION 11.24 • n=41 Participants
|
49.2 years
STANDARD_DEVIATION 11.85 • n=35 Participants
|
47.2 years
STANDARD_DEVIATION 13.35 • n=31 Participants
|
48.1 years
STANDARD_DEVIATION 13.30 • n=146 Participants
|
48.8 years
STANDARD_DEVIATION 12.61 • n=19 Participants
|
|
Sex: Female, Male
Female
|
46 Participants
n=39 Participants
|
37 Participants
n=41 Participants
|
47 Participants
n=35 Participants
|
41 Participants
n=31 Participants
|
44 Participants
n=146 Participants
|
215 Participants
n=19 Participants
|
|
Sex: Female, Male
Male
|
32 Participants
n=39 Participants
|
42 Participants
n=41 Participants
|
30 Participants
n=35 Participants
|
37 Participants
n=31 Participants
|
35 Participants
n=146 Participants
|
176 Participants
n=19 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
12 Participants
n=39 Participants
|
16 Participants
n=41 Participants
|
11 Participants
n=35 Participants
|
9 Participants
n=31 Participants
|
11 Participants
n=146 Participants
|
59 Participants
n=19 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
66 Participants
n=39 Participants
|
63 Participants
n=41 Participants
|
66 Participants
n=35 Participants
|
69 Participants
n=31 Participants
|
68 Participants
n=146 Participants
|
332 Participants
n=19 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
1 Participants
n=35 Participants
|
1 Participants
n=31 Participants
|
3 Participants
n=146 Participants
|
5 Participants
n=19 Participants
|
|
Race (NIH/OMB)
White
|
76 Participants
n=39 Participants
|
78 Participants
n=41 Participants
|
75 Participants
n=35 Participants
|
75 Participants
n=31 Participants
|
74 Participants
n=146 Participants
|
378 Participants
n=19 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=39 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=146 Participants
|
0 Participants
n=19 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=39 Participants
|
1 Participants
n=41 Participants
|
1 Participants
n=35 Participants
|
2 Participants
n=31 Participants
|
2 Participants
n=146 Participants
|
8 Participants
n=19 Participants
|
PRIMARY outcome
Timeframe: week 24Population: Cochran-Mantel-Haenszel Analysis of ACR20 Response Rate At Week 24 (Missing Response = Non-response) - Primary Analysis (Full Analysis Set)
The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate
|
0.7949 proportion of subjects
|
0.7722 proportion of subjects
|
0.7143 proportion of subjects
|
0.7308 proportion of subjects
|
0.5063 proportion of subjects
|
SECONDARY outcome
Timeframe: week 52Population: Full Analysis Set
The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
Outcome measures
| Measure |
SUNPG1623 I
n=67 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=64 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=60 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=75 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=75 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate
|
0.9254 proportion of subjects
|
0.8906 proportion of subjects
|
0.8667 proportion of subjects
|
0.8133 proportion of subjects
|
0.8133 proportion of subjects
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52Population: Cochran-Mantel-Haenszel Analysis of ACR50 Response Rates up to Week 24 Full Analysis Set. ACR50 Response Rates up to Week 52 Full Analysis Set.
The American College of Rheumatology50 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 1
|
0 proportion of subjects
|
0.0253 proportion of subjects
|
0.0130 proportion of subjects
|
0.0128 proportion of subjects
|
0 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 4
|
0.0256 proportion of subjects
|
0.0506 proportion of subjects
|
0.0909 proportion of subjects
|
0.0385 proportion of subjects
|
0.0253 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 8
|
0.1667 proportion of subjects
|
0.0759 proportion of subjects
|
0.1299 proportion of subjects
|
0.1410 proportion of subjects
|
0.0759 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 12
|
0.1795 proportion of subjects
|
0.1772 proportion of subjects
|
0.2078 proportion of subjects
|
0.1923 proportion of subjects
|
0.0633 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 16
|
0.3077 proportion of subjects
|
0.2785 proportion of subjects
|
0.2727 proportion of subjects
|
0.2051 proportion of subjects
|
0.0506 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 20
|
0.4487 proportion of subjects
|
0.4177 proportion of subjects
|
0.2857 proportion of subjects
|
0.2308 proportion of subjects
|
0.1646 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 24
|
0.5256 proportion of subjects
|
0.5063 proportion of subjects
|
0.4545 proportion of subjects
|
0.3974 proportion of subjects
|
0.2405 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
week 52
|
0.7910 proportion of subjects
|
0.7500 proportion of subjects
|
0.7213 proportion of subjects
|
0.6800 proportion of subjects
|
0.6267 proportion of subjects
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, week 24, and week 52Population: Cochran-Mantel-Haenszel Analysis of ACR70 Response Rates up to Week 24 Full Analysis Set ACR70 Response Rates up to Week 52 Full Analysis Set.
The American College of Rheumatology70 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 1
|
0 proportion of subjects
|
0.0127 proportion of subjects
|
0 proportion of subjects
|
0 proportion of subjects
|
0 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 4
|
0.0128 proportion of subjects
|
0.0127 proportion of subjects
|
0 proportion of subjects
|
0.0128 proportion of subjects
|
0.0127 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 8
|
0.0256 proportion of subjects
|
0.0380 proportion of subjects
|
0.0260 proportion of subjects
|
0.0256 proportion of subjects
|
0.0380 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 12
|
0.1026 proportion of subjects
|
0.0380 proportion of subjects
|
0.0649 proportion of subjects
|
0.1026 proportion of subjects
|
0.0127 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 16
|
0.1410 proportion of subjects
|
0.1266 proportion of subjects
|
0.1169 proportion of subjects
|
0.0897 proportion of subjects
|
0.0253 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 20
|
0.2051 proportion of subjects
|
0.2658 proportion of subjects
|
0.1429 proportion of subjects
|
0.1282 proportion of subjects
|
0.0380 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 24
|
0.2821 proportion of subjects
|
0.2911 proportion of subjects
|
0.2208 proportion of subjects
|
0.1667 proportion of subjects
|
0.1013 proportion of subjects
|
|
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
week 52
|
0.5821 proportion of subjects
|
0.4844 proportion of subjects
|
0.3934 proportion of subjects
|
0.4000 proportion of subjects
|
0.3733 proportion of subjects
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.
Outcome measures
| Measure |
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Tender Joint Counts
Week 1
|
-1.5 tender joint counts
Standard Error 0.77
|
-2.4 tender joint counts
Standard Error 0.76
|
-2.5 tender joint counts
Standard Error 0.78
|
-3.1 tender joint counts
Standard Error 0.76
|
-2.1 tender joint counts
Standard Error 0.76
|
|
Change From Baseline in Tender Joint Counts
Week 4
|
-4.7 tender joint counts
Standard Error 0.89
|
-4.9 tender joint counts
Standard Error 0.88
|
-5.4 tender joint counts
Standard Error 0.89
|
-3.9 tender joint counts
Standard Error 0.88
|
-4.1 tender joint counts
Standard Error 0.87
|
|
Change From Baseline in Tender Joint Counts
Week 8
|
-7.1 tender joint counts
Standard Error 0.94
|
-7.8 tender joint counts
Standard Error 0.92
|
-8.6 tender joint counts
Standard Error 0.94
|
-7.2 tender joint counts
Standard Error 0.93
|
-6.9 tender joint counts
Standard Error 0.91
|
|
Change From Baseline in Tender Joint Counts
Week 12
|
-8.3 tender joint counts
Standard Error 0.96
|
-10.0 tender joint counts
Standard Error 0.94
|
-8.7 tender joint counts
Standard Error 0.95
|
-7.8 tender joint counts
Standard Error 0.96
|
-7.7 tender joint counts
Standard Error 0.94
|
|
Change From Baseline in Tender Joint Counts
Week 16
|
-10.3 tender joint counts
Standard Error 1.04
|
-11.3 tender joint counts
Standard Error 1.01
|
-10.7 tender joint counts
Standard Error 1.03
|
-9.8 tender joint counts
Standard Error 1.04
|
-8.4 tender joint counts
Standard Error 1.02
|
|
Change From Baseline in Tender Joint Counts
Week 20
|
-11.2 tender joint counts
Standard Error 1.09
|
-12.3 tender joint counts
Standard Error 1.06
|
-11.5 tender joint counts
Standard Error 1.07
|
-11.4 tender joint counts
Standard Error 1.09
|
-9.9 tender joint counts
Standard Error 1.06
|
|
Change From Baseline in Tender Joint Counts
Week 24
|
-11.9 tender joint counts
Standard Error 1.04
|
-12.6 tender joint counts
Standard Error 1.01
|
-12.9 tender joint counts
Standard Error 1.03
|
-12.0 tender joint counts
Standard Error 1.04
|
-9.4 tender joint counts
Standard Error 1.02
|
SECONDARY outcome
Timeframe: Week 52Population: Full Analysis Set
Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Tender Joint Counts
|
-12.3 tender joint counts
Standard Deviation 11.47
|
-13.7 tender joint counts
Standard Deviation 11.92
|
-16.0 tender joint counts
Standard Deviation 12.83
|
-14.0 tender joint counts
Standard Deviation 10.65
|
-13.9 tender joint counts
Standard Deviation 12.02
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in Swollen Joint Counts up to Week 24 - (No Imputation) Full Analysis Set
Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.
Outcome measures
| Measure |
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Swollen Joint Counts
Week 1
|
-1.8 Swollen Joint Counts
Standard Error 0.51
|
-2.1 Swollen Joint Counts
Standard Error 0.51
|
-1.3 Swollen Joint Counts
Standard Error 0.52
|
-2.4 Swollen Joint Counts
Standard Error 0.51
|
-1.3 Swollen Joint Counts
Standard Error 0.51
|
|
Change From Baseline in Swollen Joint Counts
Week 4
|
-4.1 Swollen Joint Counts
Standard Error 0.56
|
-3.8 Swollen Joint Counts
Standard Error 0.55
|
-3.8 Swollen Joint Counts
Standard Error 0.56
|
-3.0 Swollen Joint Counts
Standard Error 0.55
|
-3.1 Swollen Joint Counts
Standard Error 0.55
|
|
Change From Baseline in Swollen Joint Counts
Week 8
|
-5.8 Swollen Joint Counts
Standard Error 0.55
|
-5.5 Swollen Joint Counts
Standard Error 0.54
|
-5.7 Swollen Joint Counts
Standard Error 0.55
|
-5.0 Swollen Joint Counts
Standard Error 0.55
|
-4.7 Swollen Joint Counts
Standard Error 0.54
|
|
Change From Baseline in Swollen Joint Counts
Week 12
|
-7.3 Swollen Joint Counts
Standard Error 0.55
|
-6.6 Swollen Joint Counts
Standard Error 0.54
|
-6.2 Swollen Joint Counts
Standard Error 0.55
|
-4.8 Swollen Joint Counts
Standard Error 0.55
|
-4.9 Swollen Joint Counts
Standard Error 0.54
|
|
Change From Baseline in Swollen Joint Counts
Week 16
|
-8.0 Swollen Joint Counts
Standard Error 0.56
|
-7.2 Swollen Joint Counts
Standard Error 0.55
|
-7.0 Swollen Joint Counts
Standard Error 0.55
|
-6.0 Swollen Joint Counts
Standard Error 0.56
|
-5.2 Swollen Joint Counts
Standard Error 0.55
|
|
Change From Baseline in Swollen Joint Counts
Week 20
|
-8.3 Swollen Joint Counts
Standard Error 0.56
|
-7.4 Swollen Joint Counts
Standard Error 0.55
|
-7.4 Swollen Joint Counts
Standard Error 0.56
|
-6.8 Swollen Joint Counts
Standard Error 0.56
|
-6.0 Swollen Joint Counts
Standard Error 0.55
|
|
Change From Baseline in Swollen Joint Counts
Week 24
|
-8.3 Swollen Joint Counts
Standard Error 0.52
|
-7.7 Swollen Joint Counts
Standard Error 0.51
|
-8.2 Swollen Joint Counts
Standard Error 0.52
|
-7.6 Swollen Joint Counts
Standard Error 0.52
|
-6.5 Swollen Joint Counts
Standard Error 0.51
|
SECONDARY outcome
Timeframe: Week 52Population: Full Analysis Set
Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Swollen Joint Counts
|
-8.7 Swollen Joint Counts
Standard Deviation 6.88
|
-7.5 Swollen Joint Counts
Standard Deviation 7.07
|
-9.2 Swollen Joint Counts
Standard Deviation 7.62
|
-7.5 Swollen Joint Counts
Standard Deviation 5.78
|
-9.0 Swollen Joint Counts
Standard Deviation 8.80
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)
Outcome measures
| Measure |
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 1
|
-7.8 scores on a visual analog scale
Standard Error 1.69
|
-8.0 scores on a visual analog scale
Standard Error 1.68
|
-7.2 scores on a visual analog scale
Standard Error 1.70
|
-6.2 scores on a visual analog scale
Standard Error 1.68
|
-4.5 scores on a visual analog scale
Standard Error 1.67
|
|
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 4
|
-14.3 scores on a visual analog scale
Standard Error 2.01
|
-15.7 scores on a visual analog scale
Standard Error 1.99
|
-15.1 scores on a visual analog scale
Standard Error 1.99
|
-14.0 scores on a visual analog scale
Standard Error 1.99
|
-9.7 scores on a visual analog scale
Standard Error 1.95
|
|
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 8
|
-21.9 scores on a visual analog scale
Standard Error 2.20
|
-23.6 scores on a visual analog scale
Standard Error 2.16
|
-23.9 scores on a visual analog scale
Standard Error 2.18
|
-20.8 scores on a visual analog scale
Standard Error 2.18
|
-16.2 scores on a visual analog scale
Standard Error 2.13
|
|
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 12
|
-27.9 scores on a visual analog scale
Standard Error 2.22
|
-28.7 scores on a visual analog scale
Standard Error 2.17
|
-27.6 scores on a visual analog scale
Standard Error 2.19
|
-23.1 scores on a visual analog scale
Standard Error 2.22
|
-18.5 scores on a visual analog scale
Standard Error 2.17
|
|
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 16
|
-31.0 scores on a visual analog scale
Standard Error 2.08
|
-32.1 scores on a visual analog scale
Standard Error 2.03
|
-31.7 scores on a visual analog scale
Standard Error 2.05
|
-30.8 scores on a visual analog scale
Standard Error 2.08
|
-20.2 scores on a visual analog scale
Standard Error 2.04
|
|
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 20
|
-36.7 scores on a visual analog scale
Standard Error 2.19
|
-36.8 scores on a visual analog scale
Standard Error 2.13
|
-31.0 scores on a visual analog scale
Standard Error 2.15
|
-33.0 scores on a visual analog scale
Standard Error 2.19
|
-24.3 scores on a visual analog scale
Standard Error 2.13
|
|
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 24
|
-36.5 scores on a visual analog scale
Standard Error 2.15
|
-38.8 scores on a visual analog scale
Standard Error 2.08
|
-37.5 scores on a visual analog scale
Standard Error 2.11
|
-36.3 scores on a visual analog scale
Standard Error 2.14
|
-23.5 scores on a visual analog scale
Standard Error 2.09
|
SECONDARY outcome
Timeframe: Week 52Population: Full Analysis Set
100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale
|
-40.0 scores on a visual analog scale
Standard Deviation 17.38
|
-44.3 scores on a visual analog scale
Standard Deviation 19.73
|
-45.3 scores on a visual analog scale
Standard Deviation 19.84
|
-42.7 scores on a visual analog scale
Standard Deviation 19.18
|
-42.0 scores on a visual analog scale
Standard Deviation 20.41
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20 and week 24100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)
Outcome measures
| Measure |
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Patient's Global Assessment of Disease Activity
Week 1
|
-5.9 scores on a visual analog scale
Standard Error 1.85
|
-7.5 scores on a visual analog scale
Standard Error 1.84
|
-6.8 scores on a visual analog scale
Standard Error 1.87
|
-6.4 scores on a visual analog scale
Standard Error 1.84
|
-2.8 scores on a visual analog scale
Standard Error 1.84
|
|
Patient's Global Assessment of Disease Activity
Week 4
|
-7.5 scores on a visual analog scale
Standard Error 2.17
|
-11.9 scores on a visual analog scale
Standard Error 2.14
|
-9.5 scores on a visual analog scale
Standard Error 2.15
|
-8.8 scores on a visual analog scale
Standard Error 2.14
|
-5.9 scores on a visual analog scale
Standard Error 2.11
|
|
Patient's Global Assessment of Disease Activity
Week 8
|
-15.4 scores on a visual analog scale
Standard Error 2.30
|
-15.5 scores on a visual analog scale
Standard Error 2.25
|
-14.5 scores on a visual analog scale
Standard Error 2.28
|
-13.1 scores on a visual analog scale
Standard Error 2.28
|
-10.1 scores on a visual analog scale
Standard Error 2.23
|
|
Patient's Global Assessment of Disease Activity
Week 12
|
-18.1 scores on a visual analog scale
Standard Error 2.52
|
-20.3 scores on a visual analog scale
Standard Error 2.46
|
-16.1 scores on a visual analog scale
Standard Error 2.49
|
-16.4 scores on a visual analog scale
Standard Error 2.51
|
-11.2 scores on a visual analog scale
Standard Error 2.46
|
|
Patient's Global Assessment of Disease Activity
Week 16
|
-23.5 scores on a visual analog scale
Standard Error 2.63
|
-22.0 scores on a visual analog scale
Standard Error 2.57
|
-18.7 scores on a visual analog scale
Standard Error 2.59
|
-19.4 scores on a visual analog scale
Standard Error 2.63
|
-13.8 scores on a visual analog scale
Standard Error 2.58
|
|
Patient's Global Assessment of Disease Activity
Week 20
|
-29.7 scores on a visual analog scale
Standard Error 2.64
|
-27.3 scores on a visual analog scale
Standard Error 2.57
|
-22.7 scores on a visual analog scale
Standard Error 2.60
|
-21.6 scores on a visual analog scale
Standard Error 2.64
|
-15.6 scores on a visual analog scale
Standard Error 2.58
|
|
Patient's Global Assessment of Disease Activity
Week 24
|
-35.0 scores on a visual analog scale
Standard Error 2.60
|
-33.3 scores on a visual analog scale
Standard Error 2.52
|
-33.4 scores on a visual analog scale
Standard Error 2.56
|
-30.4 scores on a visual analog scale
Standard Error 2.60
|
-21.7 scores on a visual analog scale
Standard Error 2.54
|
SECONDARY outcome
Timeframe: Week 52Population: Full Analysis Set
100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Patient's Global Assessment of Disease Activity
|
-42.2 scores on a visual analog scale
Standard Deviation 22.74
|
-43.8 scores on a visual analog scale
Standard Deviation 24.01
|
-38.4 scores on a visual analog scale
Standard Deviation 27.90
|
-37.9 scores on a visual analog scale
Standard Deviation 24.65
|
-40.5 scores on a visual analog scale
Standard Deviation 28.13
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in Patient's Pain Assessment up to Week 24 - (No Imputation) Full Analysis Set
100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).
Outcome measures
| Measure |
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Patient's Pain Assessment
Week 1
|
-5.8 scores on a visual analog scale
Standard Error 1.96
|
-8.1 scores on a visual analog scale
Standard Error 1.95
|
-5.1 scores on a visual analog scale
Standard Error 1.98
|
-5.8 scores on a visual analog scale
Standard Error 1.95
|
-1.6 scores on a visual analog scale
Standard Error 1.95
|
|
Patient's Pain Assessment
Week 4
|
-9.8 scores on a visual analog scale
Standard Error 2.15
|
-12.8 scores on a visual analog scale
Standard Error 2.12
|
-8.9 scores on a visual analog scale
Standard Error 2.13
|
-6.4 scores on a visual analog scale
Standard Error 2.12
|
-3.9 scores on a visual analog scale
Standard Error 2.09
|
|
Patient's Pain Assessment
Week 8
|
-16.9 scores on a visual analog scale
Standard Error 2.42
|
-16.1 scores on a visual analog scale
Standard Error 2.37
|
-16.6 scores on a visual analog scale
Standard Error 2.41
|
-11.9 scores on a visual analog scale
Standard Error 2.40
|
-8.5 scores on a visual analog scale
Standard Error 2.35
|
|
Patient's Pain Assessment
Week 12
|
-19.4 scores on a visual analog scale
Standard Error 2.54
|
-20.4 scores on a visual analog scale
Standard Error 2.48
|
-15.6 scores on a visual analog scale
Standard Error 2.50
|
-14.0 scores on a visual analog scale
Standard Error 2.53
|
-11.5 scores on a visual analog scale
Standard Error 2.48
|
|
Patient's Pain Assessment
Week 16
|
-23.8 scores on a visual analog scale
Standard Error 2.58
|
-23.2 scores on a visual analog scale
Standard Error 2.52
|
-20.6 scores on a visual analog scale
Standard Error 2.55
|
-19.3 scores on a visual analog scale
Standard Error 2.59
|
-12.8 scores on a visual analog scale
Standard Error 2.54
|
|
Patient's Pain Assessment
Week 20
|
-29.8 scores on a visual analog scale
Standard Error 2.79
|
-25.3 scores on a visual analog scale
Standard Error 2.71
|
-21.4 scores on a visual analog scale
Standard Error 2.74
|
-21.4 scores on a visual analog scale
Standard Error 2.78
|
-17.1 scores on a visual analog scale
Standard Error 2.72
|
|
Patient's Pain Assessment
Week 24
|
-35.1 scores on a visual analog scale
Standard Error 2.69
|
-31.6 scores on a visual analog scale
Standard Error 2.60
|
-32.1 scores on a visual analog scale
Standard Error 2.64
|
-28.8 scores on a visual analog scale
Standard Error 2.68
|
-21.5 scores on a visual analog scale
Standard Error 2.63
|
SECONDARY outcome
Timeframe: Week 52Population: Full Analysis Set
100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Patient's Pain Assessment
|
-40.7 scores on a visual analog scale
Standard Deviation 21.59
|
-42.7 scores on a visual analog scale
Standard Deviation 25.67
|
-38.0 scores on a visual analog scale
Standard Deviation 29.26
|
-37.6 scores on a visual analog scale
Standard Deviation 26.63
|
-41.0 scores on a visual analog scale
Standard Deviation 29.83
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do). The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability
Outcome measures
| Measure |
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Health Assessment Questionnaire- Disability Index
Week 1
|
-0.0374 score for the disability index
Standard Error 0.03454
|
-0.0453 score for the disability index
Standard Error 0.03436
|
-0.0552 score for the disability index
Standard Error 0.03492
|
-0.0411 score for the disability index
Standard Error 0.03435
|
-0.0045 score for the disability index
Standard Error 0.03439
|
|
Health Assessment Questionnaire- Disability Index
Week 4
|
-0.0025 score for the disability index
Standard Error 0.04036
|
-0.0736 score for the disability index
Standard Error 0.03984
|
-0.0906 score for the disability index
Standard Error 0.03999
|
-0.0409 score for the disability index
Standard Error 0.03989
|
-0.0404 score for the disability index
Standard Error 0.03928
|
|
Health Assessment Questionnaire- Disability Index
Week 8
|
-0.1510 score for the disability index
Standard Error 0.04709
|
-0.1279 score for the disability index
Standard Error 0.04627
|
-0.2035 score for the disability index
Standard Error 0.04687
|
-0.1041 score for the disability index
Standard Error 0.04669
|
-0.1265 score for the disability index
Standard Error 0.04588
|
|
Health Assessment Questionnaire- Disability Index
Week 12
|
-0.1310 score for the disability index
Standard Error 0.04601
|
-0.2140 score for the disability index
Standard Error 0.04507
|
-0.2090 score for the disability index
Standard Error 0.04555
|
-0.1731 score for the disability index
Standard Error 0.04597
|
-0.1374 score for the disability index
Standard Error 0.04503
|
|
Health Assessment Questionnaire- Disability Index
Week 16
|
-0.2061 score for the disability index
Standard Error 0.04890
|
-0.2448 score for the disability index
Standard Error 0.04790
|
-0.2343 score for the disability index
Standard Error 0.04843
|
-0.2102 score for the disability index
Standard Error 0.04889
|
-0.1580 score for the disability index
Standard Error 0.04801
|
|
Health Assessment Questionnaire- Disability Index
Week 20
|
-0.3052 score for the disability index
Standard Error 0.05256
|
-0.2868 score for the disability index
Standard Error 0.05128
|
-0.2911 score for the disability index
Standard Error 0.05185
|
-0.1947 score for the disability index
Standard Error 0.05244
|
-0.2271 score for the disability index
Standard Error 0.05135
|
|
Health Assessment Questionnaire- Disability Index
Week 24
|
-0.3013 score for the disability index
Standard Error 0.05196
|
-0.3314 score for the disability index
Standard Error 0.05054
|
-0.3337 score for the disability index
Standard Error 0.05128
|
-0.2376 score for the disability index
Standard Error 0.05187
|
-0.1827 score for the disability index
Standard Error 0.05102
|
SECONDARY outcome
Timeframe: Week 52Population: Full Analysis Set
eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do). The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Health Assessment Questionnaire- Disability Index
|
-0.4869 score for the disability index
Standard Deviation 0.52093
|
-0.5430 score for the disability index
Standard Deviation 0.59145
|
-0.4857 score for the disability index
Standard Deviation 0.56968
|
-0.4583 score for the disability index
Standard Deviation 0.52285
|
-0.4700 score for the disability index
Standard Deviation 0.54013
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in CRP (mg/L) up to Week 24 - (No Imputation) Full Analysis Set
C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation
Outcome measures
| Measure |
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Acute Phase C - Reactive Protein
Week 1
|
0.19 mg/L
Standard Error 0.967
|
-0.75 mg/L
Standard Error 0.961
|
-0.50 mg/L
Standard Error 0.979
|
2.08 mg/L
Standard Error 0.961
|
0.51 mg/L
Standard Error 0.964
|
|
Acute Phase C - Reactive Protein
Week 4
|
-0.71 mg/L
Standard Error 1.239
|
-3.41 mg/L
Standard Error 1.227
|
-0.82 mg/L
Standard Error 1.223
|
0.64 mg/L
Standard Error 1.222
|
-0.28 mg/L
Standard Error 1.206
|
|
Acute Phase C - Reactive Protein
Week 8
|
-2.96 mg/L
Standard Error 1.506
|
-3.21 mg/L
Standard Error 1.476
|
-1.54 mg/L
Standard Error 1.502
|
1.95 mg/L
Standard Error 1.495
|
1.24 mg/L
Standard Error 1.465
|
|
Acute Phase C - Reactive Protein
Week 12
|
-2.21 mg/L
Standard Error 1.121
|
-3.04 mg/L
Standard Error 1.097
|
-2.59 mg/L
Standard Error 1.104
|
0.11 mg/L
Standard Error 1.124
|
1.49 mg/L
Standard Error 1.097
|
|
Acute Phase C - Reactive Protein
Week 16
|
-3.37 mg/L
Standard Error 1.505
|
-3.57 mg/L
Standard Error 1.462
|
-1.67 mg/L
Standard Error 1.485
|
-1.58 mg/L
Standard Error 1.505
|
2.25 mg/L
Standard Error 1.474
|
|
Acute Phase C - Reactive Protein
Week 20
|
-3.72 mg/L
Standard Error 1.708
|
-2.76 mg/L
Standard Error 1.656
|
-2.57 mg/L
Standard Error 1.677
|
-0.61 mg/L
Standard Error 1.715
|
4.60 mg/L
Standard Error 1.672
|
|
Acute Phase C - Reactive Protein
Week 24
|
-3.56 mg/L
Standard Error 1.088
|
-2.33 mg/L
Standard Error 1.054
|
-3.23 mg/L
Standard Error 1.071
|
-2.06 mg/L
Standard Error 1.088
|
0.55 mg/L
Standard Error 1.065
|
SECONDARY outcome
Timeframe: Week 52C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation. Change from Baseline in C-Reactive Protein.
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Acute Phase C - Reactive Protein
|
-3.43 mg/L
Standard Deviation 12.506
|
-3.68 mg/L
Standard Deviation 10.770
|
-6.05 mg/L
Standard Deviation 19.004
|
-4.61 mg/L
Standard Deviation 9.508
|
-6.75 mg/L
Standard Deviation 19.649
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in ESR (mm/hr) up to Week 24 - (No Imputation) Full Analysis Set
An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.
Outcome measures
| Measure |
SUNPG1623 I
n=70 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=68 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=69 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=68 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=62 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Erythrocyte Sedimentation Rate
Week 1
|
-3.1 mm/hr
Standard Error 1.39
|
-3.0 mm/hr
Standard Error 1.40
|
-3.3 mm/hr
Standard Error 1.41
|
-1.1 mm/hr
Standard Error 1.41
|
-2.6 mm/hr
Standard Error 1.45
|
|
Erythrocyte Sedimentation Rate
Week 4
|
-6.9 mm/hr
Standard Error 1.46
|
-5.9 mm/hr
Standard Error 1.48
|
-5.5 mm/hr
Standard Error 1.45
|
-5.6 mm/hr
Standard Error 1.47
|
-4.8 mm/hr
Standard Error 1.51
|
|
Erythrocyte Sedimentation Rate
Week 8
|
-8.7 mm/hr
Standard Error 1.58
|
-6.5 mm/hr
Standard Error 1.58
|
-7.1 mm/hr
Standard Error 1.58
|
-5.5 mm/hr
Standard Error 1.60
|
-3.6 mm/hr
Standard Error 1.64
|
|
Erythrocyte Sedimentation Rate
Week 12
|
-8.6 mm/hr
Standard Error 1.59
|
-6.8 mm/hr
Standard Error 1.59
|
-7.9 mm/hr
Standard Error 1.58
|
-6.6 mm/hr
Standard Error 1.62
|
-2.3 mm/hr
Standard Error 1.66
|
|
Erythrocyte Sedimentation Rate
Week 16
|
-9.4 mm/hr
Standard Error 1.93
|
-8.4 mm/hr
Standard Error 1.92
|
-8.3 mm/hr
Standard Error 1.91
|
-6.0 mm/hr
Standard Error 1.96
|
-3.3 mm/hr
Standard Error 2.02
|
|
Erythrocyte Sedimentation Rate
Week 20
|
-9.6 mm/hr
Standard Error 1.73
|
-7.2 mm/hr
Standard Error 1.72
|
-9.2 mm/hr
Standard Error 1.71
|
-8.5 mm/hr
Standard Error 1.76
|
-4.4 mm/hr
Standard Error 1.81
|
|
Erythrocyte Sedimentation Rate
Week 24
|
-8.0 mm/hr
Standard Error 1.86
|
-6.9 mm/hr
Standard Error 1.85
|
-8.2 mm/hr
Standard Error 1.84
|
-8.7 mm/hr
Standard Error 1.89
|
-2.3 mm/hr
Standard Error 1.95
|
SECONDARY outcome
Timeframe: Week 52Population: Full Analysis Set
An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Erythrocyte Sedimentation Rate
|
-7.2 mm/hr
Standard Deviation 19.58
|
-7.2 mm/hr
Standard Deviation 15.26
|
-8.9 mm/hr
Standard Deviation 20.48
|
-9.7 mm/hr
Standard Deviation 19.02
|
-9.2 mm/hr
Standard Deviation 20.47
|
SECONDARY outcome
Timeframe: Week 16Population: Subjects Who Require Adjustment of Background Therapy at Week 16 Full Analysis Set
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
The Proportion of Subjects Who Require Adjustment of Background Therapy
|
0 proportion of subjects
|
0.0127 proportion of subjects
|
0.0130 proportion of subjects
|
0.0256 proportion of subjects
|
0.0127 proportion of subjects
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and Week 52Population: Cochran-Mantel-Haenszel Analysis of DAS28-CRP Response Rates up to Week 24 Full Analysis Set. DAS28-CRP Response Rates up to Week 52-Full Analysis Set
The Disease Activity Score 28-item C-Reactive Protein: assessed across 28 joints including the shoulder, elbow, wrist, MCP (1 through 5), PIP (1 through 5) and knee, with all 14 joints assessed for each side of the body. It is a composite score derived from examination of the 28 joints for swelling and tenderness, global assessment of pain and overall status using a VAS and a blood marker of inflammation (hsCRP). DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 TJC- tender joint count, SJC- swollen joint count, CRP- C reactive protein, GH - patient global health
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 12
|
38.46 percentage of participants
|
40.51 percentage of participants
|
31.17 percentage of participants
|
29.49 percentage of participants
|
18.99 percentage of participants
|
|
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 16
|
48.72 percentage of participants
|
48.10 percentage of participants
|
36.36 percentage of participants
|
35.90 percentage of participants
|
13.92 percentage of participants
|
|
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 8
|
35.90 percentage of participants
|
29.11 percentage of participants
|
29.87 percentage of participants
|
23.08 percentage of participants
|
18.99 percentage of participants
|
|
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 20
|
60.26 percentage of participants
|
60.76 percentage of participants
|
37.66 percentage of participants
|
43.59 percentage of participants
|
21.52 percentage of participants
|
|
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 24
|
58.97 percentage of participants
|
64.56 percentage of participants
|
58.44 percentage of participants
|
53.85 percentage of participants
|
30.38 percentage of participants
|
|
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 52
|
85.07 percentage of participants
|
81.25 percentage of participants
|
76.27 percentage of participants
|
71.05 percentage of participants
|
65.33 percentage of participants
|
|
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 1
|
11.54 percentage of participants
|
12.66 percentage of participants
|
10.39 percentage of participants
|
5.13 percentage of participants
|
6.33 percentage of participants
|
|
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 4
|
20.51 percentage of participants
|
17.72 percentage of participants
|
15.58 percentage of participants
|
15.38 percentage of participants
|
13.92 percentage of participants
|
SECONDARY outcome
Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52Population: Cochran-Mantel-Haenszel Analysis of MDA Response Rates up to Week 24 (Missing Response = Non-response) Full Analysis Set. MDA Response Rates up to Week 52- Full Analysis Set
A psoriatic arthritis patient is defined as having a Minimal Disease Activity (MDA) response (Yes/No) when the patient meets at least 5 of the 7 following criteria: 1. tender joint count ≤1; 2. swollen joint count ≤1; 3. PASI score ≤1 or BSA ≤3%; 4. patient Arthritis Pain (VAS) ≤15 mm; 5. patient's global arthritis assessment (VAS) ≤20 mm; 6. HAQ-DI score ≤0.5; 7. tender entheseal points (using LEI) ≤1.
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Minimal Disease Activity
Week 1
|
0 percentage of participants
|
1.27 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
0 percentage of participants
|
|
Minimal Disease Activity
Week 4
|
3.85 percentage of participants
|
1.27 percentage of participants
|
1.30 percentage of participants
|
2.56 percentage of participants
|
1.27 percentage of participants
|
|
Minimal Disease Activity
Week 8
|
3.85 percentage of participants
|
2.53 percentage of participants
|
2.60 percentage of participants
|
0 percentage of participants
|
2.53 percentage of participants
|
|
Minimal Disease Activity
Week 12
|
12.82 percentage of participants
|
8.86 percentage of participants
|
7.79 percentage of participants
|
8.97 percentage of participants
|
2.53 percentage of participants
|
|
Minimal Disease Activity
Week 16
|
12.82 percentage of participants
|
6.33 percentage of participants
|
7.79 percentage of participants
|
8.97 percentage of participants
|
1.27 percentage of participants
|
|
Minimal Disease Activity
Week 20
|
17.95 percentage of participants
|
15.19 percentage of participants
|
9.09 percentage of participants
|
8.97 percentage of participants
|
2.53 percentage of participants
|
|
Minimal Disease Activity
Week 24
|
33.33 percentage of participants
|
34.18 percentage of participants
|
28.57 percentage of participants
|
19.23 percentage of participants
|
6.33 percentage of participants
|
|
Minimal Disease Activity
week 52
|
56.92 percentage of participants
|
64.41 percentage of participants
|
45.00 percentage of participants
|
47.06 percentage of participants
|
42.03 percentage of participants
|
SECONDARY outcome
Timeframe: week 4, week 12, and week 24Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in LDI up to Week 24 - (No Imputation) Full Analysis Set
tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw) Total score= {\[Circumference involved digit/ Circumference contralateral Digit (or Tables)\] - 1x 100}x Tenderness score Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45 The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index. Lower Leeds Dactylitis Index score represent better outcome.
Outcome measures
| Measure |
SUNPG1623 I
n=53 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=56 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=46 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=48 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=54 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Leeds Dactylitis Index (LDI)
Week 4
|
-17.385 score on a scale
Standard Error 9.8336
|
-17.918 score on a scale
Standard Error 9.5818
|
-19.150 score on a scale
Standard Error 10.4630
|
-5.385 score on a scale
Standard Error 10.2843
|
19.891 score on a scale
Standard Error 9.6640
|
|
Change From Baseline in Leeds Dactylitis Index (LDI)
Week 12
|
-21.041 score on a scale
Standard Error 7.8359
|
-23.163 score on a scale
Standard Error 7.5635
|
-23.948 score on a scale
Standard Error 8.3579
|
-9.982 score on a scale
Standard Error 8.2513
|
-2.990 score on a scale
Standard Error 7.7362
|
|
Change From Baseline in Leeds Dactylitis Index (LDI)
Week 24
|
-22.987 score on a scale
Standard Error 3.5112
|
-25.123 score on a scale
Standard Error 3.2307
|
-27.572 score on a scale
Standard Error 3.5088
|
-19.873 score on a scale
Standard Error 3.4520
|
-24.706 score on a scale
Standard Error 3.2252
|
SECONDARY outcome
Timeframe: Week 52Population: Full Analysis Set
tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw) Total score= {\[Circumference involved digit/ Circumference contralateral Digit (or Tables)\] - 1x 100}x Tenderness score Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45 The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index. Lower Leeds Dactylitis Index score represent better outcome.
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Leeds Dactylitis Index (LDI)
|
-14.453 score on a scale
Standard Deviation 31.9358
|
-18.883 score on a scale
Standard Deviation 57.1147
|
-27.084 score on a scale
Standard Deviation 76.2272
|
-26.173 score on a scale
Standard Deviation 87.5367
|
-50.399 score on a scale
Standard Deviation 141.6770
|
SECONDARY outcome
Timeframe: week 4, week 12 and week 24Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in LEI up to Week 24 - (No Imputation) Full Analysis Set
The LEI examines tenderness at 6 sites: 2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6. Lower the score better is the outcome
Outcome measures
| Measure |
SUNPG1623 I
n=72 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=77 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=75 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=76 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=78 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Leeds Enthesitis Index (LEI)
Week 4
|
-0.5 score on a scale
Standard Error 0.15
|
-0.4 score on a scale
Standard Error 0.14
|
-0.5 score on a scale
Standard Error 0.14
|
-0.4 score on a scale
Standard Error 0.14
|
-0.4 score on a scale
Standard Error 0.14
|
|
Change From Baseline in Leeds Enthesitis Index (LEI)
Week 12
|
-0.8 score on a scale
Standard Error 0.15
|
-0.7 score on a scale
Standard Error 0.14
|
-0.9 score on a scale
Standard Error 0.15
|
-0.8 score on a scale
Standard Error 0.15
|
-0.7 score on a scale
Standard Error 0.14
|
|
Change From Baseline in Leeds Enthesitis Index (LEI)
Week 24
|
-1.3 score on a scale
Standard Error 0.16
|
-0.9 score on a scale
Standard Error 0.15
|
-1.2 score on a scale
Standard Error 0.15
|
-1.1 score on a scale
Standard Error 0.15
|
-0.8 score on a scale
Standard Error 0.15
|
SECONDARY outcome
Timeframe: Week 52Population: Full Analysis Set
The LEI examines tenderness at 6 sites: 2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6. Lower the score better is the outcome
Outcome measures
| Measure |
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
|---|---|---|---|---|---|
|
Change From Baseline in Leeds Enthesitis Index (LEI)
|
-1.3 score on a scale
Standard Deviation 1.86
|
-1.0 score on a scale
Standard Deviation 1.56
|
-1.7 score on a scale
Standard Deviation 2.08
|
-1.2 score on a scale
Standard Deviation 1.75
|
-1.2 score on a scale
Standard Deviation 1.82
|
Adverse Events
Part 1: SUNPG1623 I
Part 1 : SUNPG1623 II
Part 1 : SUNPG1623 Dose III
Part 1 : SUNPG1623 Dose IV
Part 1 : Placebo
Part 2: SUNPG1623 I
Part 2 : SUNPG1623 II
Part 2 : SUNPG1623 Dose III
Part 2: Week 24 - 48: SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24
Part 2: Week 24 - 48: Placebo Moved to SUNPG1623 II After Week 24
Part 3: SUNPG1623 I
Part 3 : SUNPG1623 II
Part 3 : SUNPG1623 Dose III
Part 3 :Wash-out Period (SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24)
Part 3 : Wash-out Period (Placebo Moved to SUNPG1623 II After Week 24)
Serious adverse events
| Measure |
Part 1: SUNPG1623 I
n=78 participants at risk
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
Part 1 : SUNPG1623 II
n=79 participants at risk
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Part 1 : SUNPG1623 Dose III
n=77 participants at risk
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Part 1 : SUNPG1623 Dose IV
n=78 participants at risk
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Part 1 : Placebo
n=79 participants at risk
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Part 2: SUNPG1623 I
n=78 participants at risk
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
Part 2 : SUNPG1623 II
n=79 participants at risk
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Part 2 : SUNPG1623 Dose III
n=77 participants at risk
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Part 2: Week 24 - 48: SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24
n=78 participants at risk
Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Part 2: Week 24 - 48: Placebo Moved to SUNPG1623 II After Week 24
n=79 participants at risk
Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Part 3: SUNPG1623 I
n=78 participants at risk
Wash-out period
|
Part 3 : SUNPG1623 II
n=79 participants at risk
Wash-out period
|
Part 3 : SUNPG1623 Dose III
n=77 participants at risk
Wash-out period
|
Part 3 :Wash-out Period (SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24)
n=78 participants at risk
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 2 : Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 3 : wash-out period
|
Part 3 : Wash-out Period (Placebo Moved to SUNPG1623 II After Week 24)
n=79 participants at risk
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 2 : Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 3 : wash-out period
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Infections and infestations
Chronic tonsillitis
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/77 • Number of events 1 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/77 • Number of events 1 • 72 week
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • Number of events 1 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal proliferative breast lesion
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour benign
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • Number of events 1 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Nervous system disorders
Lumbar radiculopathy
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Nervous system disorders
Syncope
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/77 • Number of events 1 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Reproductive system and breast disorders
Ovarian cyst
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Pregnancy, puerperium and perinatal conditions
Ovarian cyst ruptured
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • Number of events 1 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Vascular disorders
Hypertension
|
0.00%
0/78 • 72 week
|
2.5%
2/79 • Number of events 2 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • Number of events 1 • 72 week
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
General disorders
Chest pain
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • Number of events 1 • 72 week
|
|
Infections and infestations
Bronchitis
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Infections and infestations
Pneumonia
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/77 • Number of events 1 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Infections and infestations
Toxicity to various agents
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Nervous system disorders
Multiple sclerosis
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • Number of events 1 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/78 • Number of events 1 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
Other adverse events
| Measure |
Part 1: SUNPG1623 I
n=78 participants at risk
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
Part 1 : SUNPG1623 II
n=79 participants at risk
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Part 1 : SUNPG1623 Dose III
n=77 participants at risk
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Part 1 : SUNPG1623 Dose IV
n=78 participants at risk
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Part 1 : Placebo
n=79 participants at risk
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Part 2: SUNPG1623 I
n=78 participants at risk
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
|
Part 2 : SUNPG1623 II
n=79 participants at risk
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Part 2 : SUNPG1623 Dose III
n=77 participants at risk
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
|
Part 2: Week 24 - 48: SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24
n=78 participants at risk
Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Part 2: Week 24 - 48: Placebo Moved to SUNPG1623 II After Week 24
n=79 participants at risk
Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
|
Part 3: SUNPG1623 I
n=78 participants at risk
Wash-out period
|
Part 3 : SUNPG1623 II
n=79 participants at risk
Wash-out period
|
Part 3 : SUNPG1623 Dose III
n=77 participants at risk
Wash-out period
|
Part 3 :Wash-out Period (SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24)
n=78 participants at risk
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 2 : Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 3 : wash-out period
|
Part 3 : Wash-out Period (Placebo Moved to SUNPG1623 II After Week 24)
n=79 participants at risk
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 2 : Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 3 : wash-out period
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
6.4%
5/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • 72 week
|
|
Infections and infestations
Nasopharyngitis
|
9.0%
7/78 • 72 week
|
1.3%
1/79 • 72 week
|
5.2%
4/77 • 72 week
|
6.4%
5/78 • 72 week
|
6.3%
5/79 • 72 week
|
2.6%
2/78 • 72 week
|
2.5%
2/79 • 72 week
|
2.6%
2/77 • 72 week
|
9.0%
7/78 • 72 week
|
3.8%
3/79 • 72 week
|
2.6%
2/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/77 • 72 week
|
1.3%
1/78 • 72 week
|
1.3%
1/79 • 72 week
|
|
Infections and infestations
Upper respiratory tract infection
|
2.6%
2/78 • 72 week
|
5.1%
4/79 • 72 week
|
3.9%
3/77 • 72 week
|
3.8%
3/78 • 72 week
|
1.3%
1/79 • 72 week
|
3.8%
3/78 • 72 week
|
5.1%
4/79 • 72 week
|
2.6%
2/77 • 72 week
|
5.1%
4/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/77 • 72 week
|
2.6%
2/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Nervous system disorders
Headache
|
5.1%
4/78 • 72 week
|
1.3%
1/79 • 72 week
|
6.5%
5/77 • 72 week
|
6.4%
5/78 • 72 week
|
3.8%
3/79 • 72 week
|
1.3%
1/78 • 72 week
|
3.8%
3/79 • 72 week
|
2.6%
2/77 • 72 week
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • 72 week
|
3.8%
3/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/77 • 72 week
|
1.3%
1/78 • 72 week
|
2.5%
2/79 • 72 week
|
|
Psychiatric disorders
Sleep Disorder
|
1.3%
1/78 • 72 week
|
6.3%
5/79 • 72 week
|
0.00%
0/77 • 72 week
|
1.3%
1/78 • 72 week
|
1.3%
1/79 • 72 week
|
1.3%
1/78 • 72 week
|
1.3%
1/79 • 72 week
|
0.00%
0/77 • 72 week
|
1.3%
1/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
|
Vascular disorders
Hypertension
|
3.8%
3/78 • 72 week
|
7.6%
6/79 • 72 week
|
1.3%
1/77 • 72 week
|
2.6%
2/78 • 72 week
|
6.3%
5/79 • 72 week
|
5.1%
4/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
1.3%
1/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
1.3%
1/78 • 72 week
|
1.3%
1/79 • 72 week
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • 72 week
|
3.9%
3/77 • 72 week
|
1.3%
1/78 • 72 week
|
3.8%
3/79 • 72 week
|
1.3%
1/78 • 72 week
|
1.3%
1/79 • 72 week
|
0.00%
0/77 • 72 week
|
5.1%
4/78 • 72 week
|
1.3%
1/79 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
3.8%
3/78 • 72 week
|
2.5%
2/79 • 72 week
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
0.00%
0/79 • 72 week
|
2.6%
2/78 • 72 week
|
0.00%
0/79 • 72 week
|
0.00%
0/77 • 72 week
|
2.6%
2/78 • 72 week
|
5.1%
4/79 • 72 week
|
2.6%
2/78 • 72 week
|
1.3%
1/79 • 72 week
|
0.00%
0/77 • 72 week
|
0.00%
0/78 • 72 week
|
1.3%
1/79 • 72 week
|
Additional Information
Head-Clinical Development
Sun Pharma Advanced Research Company Limited
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: OTHER